Other
2027
Merck & Co. 2027 remained flat by 0.0% to $2.60B in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $2.60B to $2.60B. Over 5 years (FY 2020 to FY 2025), 2027 shows an upward trend with a 2.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ4 2015
Last reportedQ4 2025Feb 24, 2026
How to read this metric
High maturity amounts in a single year can signal potential liquidity pressure if cash flow is insufficient for repayment or refinancing.
Detailed definition
This represents the specific portion of long-term debt principal scheduled for repayment during the 2027 fiscal year. It...
Peer comparison
Companies with staggered debt maturity profiles are generally viewed as having lower refinancing risk than those with large 'bullet' maturities.
Metric ID:
other_long_term_debt_maturities_repayments_of_principal__d4f4c9Historical Data
5 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $2.30B | $1.70B | $1.40B | $2.60B | $2.60B |
| QoQ Change | — | -26.1% | -17.6% | +85.7% | +0.0% |
| YoY Change | — | -26.1% | -17.6% | +85.7% | +0.0% |
Range$1.40B – $2.60B
CAGR+13.0%
Avg YoY Growth+10.5%
Median YoY Growth-8.8%
Current Streak2 quarters growth
2027 at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s 2027?
- Merck & Co. (MRK) reported 2027 of $2.60B in Q4 2025.
- How has Merck & Co.'s 2027 changed year-over-year?
- Merck & Co.'s 2027 decreased by 0.0% year-over-year, from $2.60B to $2.60B.
- What is the long-term trend for Merck & Co.'s 2027?
- Over 5 years (2020 to 2025), Merck & Co.'s 2027 has grown at a 2.5% compound annual growth rate (CAGR), from $2.30B to $2.60B.
- What does 2027 mean?
- The amount of long-term debt principal that must be repaid in 2027.